Pure Global
NCT05811442

Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

A Phase IIa, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 50561 in Patients With Mild or Moderate Alzheimer's Disease
Beijing Joekai Biotechnology LLC·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Alzheimer's Disease
Drug/Device/Intervention
50561 high dose
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Beijing Joekai Biotechnology LLC
Location
Beijing,Beijing,Beijing,Beijing,Guangzhou,Wuhan,Suzhou,Chang chun,Shanghai,Tianjin,Hangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 01, 2023
End date
Jun 01, 2024
Enrollment
60 participants
Primary outcome

Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog 13)

Summary

This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study
 designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in
 participants diagnosed with mild to moderate Alzheimer's disease.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05811442
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05811442 through Pure Global AI's free database. This Phase 2 trial is sponsored by Beijing Joekai Biotechnology LLC and is currently Recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.